PI
ATYR

Putnam Investments’s aTyr Pharma ATYR Stock Holding History

Putnam Investments’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-3,674
Closed -$528K – 1495
2015
Q3 		$528K Buy
3,674
+127
+4% +$28.9K ﹤0.01% 1330
2015
Q2 		$920K Buy
+3,547
New +$1.1M ﹤0.01% 1238

Other funds holding ATYR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RCM
Riverhead Capital Management Wilmington, Delaware $2.71B AUM 2.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Putnam Investments's ATYR Position: Q4 2015 in Review

Putnam Investments sold out of aTyr Pharma (ATYR) in Q4 2015, closing a stake of 3,674 shares — an estimated $528K sold.

Putnam Investments first reported a position in ATYR in Q2 2015 and held it in 2 quarters. The position peaked at $920K in Q2 2015. 50 funds tracked by Wall St. Rank hold ATYR as of Q4 2015.

  • Putnam Investments reported no remaining aTyr Pharma position as of Q4 2015 after selling out during the quarter.
  • Putnam Investments sold 3,674 aTyr Pharma shares in Q4 2015, an estimated $528K.
  • Putnam Investments first reported a position in aTyr Pharma in Q2 2015 and held it in 2 quarters.
  • Putnam Investments's aTyr Pharma position peaked at $920K in Q2 2015.
  • 50 funds tracked by Wall St. Rank held aTyr Pharma as of Q4 2015.

Based on Putnam Investments's 13F filing for Q4 2015, filed 16 Feb 2016.